NASDAQ:UNCY

Unicycive Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy UNCY

*Your capital is at risk

$7.87

+1.02 (+14.89%)

At Close: Jun 22, 2026

Unicycive Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.60. In total, the insiders bought 161.89M and sold 2.93M UNCY shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.60
● Buy	161.89M shares
● Sell	2.93M shares
92% Buy Activity Weak Positive Correlation
Buy Signal High Confidence May 14, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.6. Confidence increased due to high data reliability score of 90. Supported by overwhelming buy-side pressure (92% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 28, 2025 Buy	Stock Options A-Award	Jermasek Douglas EVP Of Corporate Strategy	Officer	10 000 Value: $47.1K
Feb 18, 2025 Buy	Common Stock C-Conversion	Aggarwal Gaurav Director	Director	1 400 000 Value: $866.7K
Feb 18, 2025 Sell	Series A-2 Prime Preferred Stock D-Return	Aggarwal Gaurav Director	Director	686 Value: $336
Feb 18, 2025 Buy	Common Stock C-Conversion	Aggarwal Gaurav Director	Director	1 400 000 Value: $866.7K
Feb 18, 2025 Sell	Series A-2 Prime Preferred Stock D-Return	Aggarwal Gaurav Director	Director	686 Value: $336
Oct 09, 2024 Buy	Common Stock C-Conversion	Aggarwal Gaurav Director	Director	5 500 000 Value: $5.50B
Oct 09, 2024 Sell	Series A-2 Prime Preferred Stock D-Return	Aggarwal Gaurav Director	Director	2 695 Value: $1K
Oct 09, 2024 Buy	Common Stock C-Conversion	Aggarwal Gaurav Director	Director	5 500 000 Value: $5.50B
Oct 09, 2024 Sell	Series A-2 Prime Preferred Stock D-Return	Aggarwal Gaurav Director	Director	2 695 Value: $1K
Aug 12, 2024 Buy	Stock Options A-Award	Townsend John Chief Financial Officer	C-Suite Officer	40 256 Value: $13.7K
Aug 12, 2024 Buy	Stock Options A-Award	Gupta Pramod EVP, Pharmaceuticals And Bd	Officer	81 750 Value: $27.8K
Aug 12, 2024 Buy	Stock Options A-Award	Jermasek Douglas EVP Of Corporate Strategy	Officer	81 750 Value: $27.8K
Aug 12, 2024 Buy	Stock Options A-Award	Gupta Shalabh K. CEO	CEO / President	232 868 Value: $79.2K
Aug 12, 2024 Buy	Stock Options A-Award	Townsend John Chief Financial Officer	C-Suite Officer	40 256 Value: $13.7K
Aug 12, 2024 Buy	Stock Options A-Award	Gupta Pramod EVP, Pharmaceuticals And Bd	Officer	81 750 Value: $27.8K
Aug 12, 2024 Buy	Stock Options A-Award	Jermasek Douglas EVP Of Corporate Strategy	Officer	81 750 Value: $27.8K
Aug 12, 2024 Buy	Stock Options A-Award	Gupta Shalabh K. CEO	CEO / President	232 868 Value: $79.2K
Apr 15, 2024 Buy	Stock Options A-Award	Townsend John Chief Financial Officer	C-Suite Officer	228 119 Value: $260.1K
Apr 15, 2024 Buy	Stock Options A-Award	Jermasek Douglas EVP Of Corporate Strategy	Officer	463 250 Value: $528.1K
Apr 15, 2024 Buy	Stock Options A-Award	Gupta Pramod EVP, Pharmaceuticals And Bd	Officer	463 250 Value: $528.1K
Apr 15, 2024 Buy	Stock Options A-Award	Gupta Shalabh K. CEO	CEO / President	1 319 583 Value: $1.50M
Apr 15, 2024 Buy	Stock Options A-Award	Townsend John Chief Financial Officer	C-Suite Officer	228 119 Value: $260.1K
Apr 15, 2024 Buy	Stock Options A-Award	Jermasek Douglas EVP Of Corporate Strategy	Officer	463 250 Value: $528.1K
Apr 15, 2024 Buy	Stock Options A-Award	Gupta Pramod EVP, Pharmaceuticals And Bd	Officer	463 250 Value: $528.1K
Apr 15, 2024 Buy	Stock Options A-Award	Gupta Shalabh K. CEO	CEO / President	1 319 583 Value: $1.50M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT UNICYCIVE THERAPEUTICS, INC.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California....

Read Full Profile Here